Table 2.
ORs by HPV16 Serology Status for Cancer of the Oral Cavity, Oropharynx, Larynx, and Esophagus
| Serology Status | Controls (n = 1,599) |
Oral Cavity Cancer (n = 180) |
Oropharynx Cancer (n = 135) |
Larynx Cancer (n = 247)* |
Esophageal Cancer (n = 300) |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of Participants | % | No. of Patients | % | OR | 95% CI | No. of Patients | % | OR | 95% CI | No. of Patients | % | OR | 95% CI | No. of Patients | % | OR | 95% CI | |
| HPV16 oncoproteins | ||||||||||||||||||
| E6 | ||||||||||||||||||
| Seronegative | 1,590 | 99.4 | 178 | 98.9 | 1 | 88 | 65.2 | 1 | 244 | 98.8 | 1 | 299 | 99.7 | 1 | ||||
| Seropositive | 9 | 0.6 | 2 | 1.1 | 1.3 | 0.3 to 6.9 | 47 | 34.8 | 274 | 110 to 681 | 3 | 1.2 | 3.8 | 0.8 to 17.6 | 1 | 0.3 | 0.6 | .1 to 5.2 |
| E7 | ||||||||||||||||||
| Seronegative | 1,421 | 88.9 | 155 | 86.1 | 1 | 108 | 80.0 | 1 | 217 | 87.9 | 1 | 272 | 90.7 | 1 | ||||
| Seropositive | 178 | 11.1 | 25 | 13.9 | 1.2 | 0.7 to 1.9 | 27 | 20.0 | 2.4 | 1.5 to 3.9 | 30 | 12.1 | 0.9 | 0.5 to 1.4 | 28 | 9.3 | 0.7 | 0.5 to 1.2 |
| HPV16 other early proteins | ||||||||||||||||||
| E1 | ||||||||||||||||||
| Seronegative | 1,536 | 96.1 | 165 | 91.7 | 1 | 113 | 83.7 | 1 | 226 | 91.5 | 1 | 283 | 94.3 | 1 | ||||
| Seropositive | 63 | 3.9 | 15 | 8.3 | 2.1 | 1.1 to 3.9 | 22 | 16.3 | 5.7 | 3.2 to 10.0 | 21 | 8.5 | 2.2 | 1.2 to 3.9 | 17 | 5.7 | 1.7 | 0.9 to 3.0 |
| E2 | ||||||||||||||||||
| Seronegative | 1,527 | 95.5 | 170 | 94.4 | 1 | 102 | 75.6 | 1 | 234 | 94.7 | 1 | 286 | 95.3 | 1 | ||||
| Seropositive | 72 | 4.5 | 10 | 5.6 | 1.0 | 0.5 to 2.1 | 33 | 24.4 | 9.5 | 5.7 to 15.8 | 13 | 5.3 | 1.0 | 0.5 to 1.9 | 14 | 4.7 | 0.9 | 0.5 to 1.7 |
| E4 | ||||||||||||||||||
| Seronegative | 1,437 | 89.9 | 165 | 91.7 | 1 | 120 | 88.9 | 1 | 218 | 88.3 | 1 | 276 | 92.0 | 1 | ||||
| Seropositive | 162 | 10.1 | 15 | 8.3 | 0.8 | 0.5 to 1.5 | 15 | 11.1 | 1.3 | 0.7 to 2.4 | 29 | 11.7 | 1.2 | 0.7 to 1.9 | 24 | 8.0 | 0.8 | 0.5 to 1.2 |
| HPV16 late protein | ||||||||||||||||||
| L1 | ||||||||||||||||||
| Seronegative | 1,270 | 79.4 | 138 | 76.7 | 1 | 79 | 58.5 | 1 | 187 | 75.7 | 1 | 231 | 77.0 | 1 | ||||
| Seropositive | 329 | 20.6 | 42 | 23.3 | 1.2 | 0.8 to 1.7 | 56 | 41.5 | 3.1 | 2.1 to 4.5 | 60 | 24.3 | 1.3 | 0.9 to 1.8 | 69 | 23.0 | 1.1 | 0.8 to 1.6 |
NOTE. All ORs were adjusted for sex, age at enrollment (in 5-year age categories), country, tobacco (never, former, current), and alcohol use (never/ever and continuous values in gm/day at recruitment).
Abbreviations: HPV, human papillomavirus; OR, odds ratio.
*
The larynx cancer category includes 31 participants with hypopharyngeal cancer.